CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: March 18, 2013
Result type: Reports
Project Number: SF0321-00
Product Line: Reimbursement Review

Generic Name: Rivaroxaban

Brand Name: Xarelto

Manufacturer: Bayer Inc.

Indications: stroke prevention in patients with atrial fibrillation.

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: July 18, 2013

Recommendation Type: List with clinical criteria and/or conditions